Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 10
Submit an article Journal homepage
24
Views
2
CrossRef citations to date
0
Altmetric
Meeting Report

SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer’s and Parkinson’s disease

Michael J O’Neill Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey. [email protected]
Pages 1369-1373 | Published online: 24 Feb 2005

  • COURTNEY C, FARRELL1D, GRAY R et al: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet (2004) 363(9427):2105–2115.
  • ••Interesting review on the overall benefit ofacetycholinesterase inhibiton in Alzheimer's disease.
  • DAWSON TM, DAWSON VL: Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 302(5646):819–822.
  • ••Good summary of molecular pathwayscontributing to Parkinson's disease.
  • VALENTE EM, ABOU-SLEIMAN PM, CAPUTO V et al.: Hereditary early-onset parkinson's disease caused by mutations in PINK 1. Science (2004) 304(5674):1158–1160.
  • WOLFE MS, XIA WM, MOORE CL et al.: Peptidomimetic probes and molecular modeling suggest that Alzheimer's y-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry (1999) 38(15):4720–4727.
  • SHEARMAN MS, BEHER D, CLARKE EE et al: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid 13-protein precursor y-secretase activity. Biochemistry (2000) 39(30):8698–8704.
  • SEIFFERT D, BRADLEY JD, ROMINGER CM et al.: Presenilin-1 and -2 are molecular targets for y-secretase inhibitors. Biol. Chem. (2000) 275(4034086–34091.
  • TIAN GC, SOBOTKA-BRINER CD, ZYSK J et al: Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin a methylester, L-685,458, sulfonamides, and benzodiazepines. J. Biol. Chem. (2002) 277(35):31499–31505.
  • BEHER D, WRIGLEY JDJ, OWENS AP, SHEARMAN MS: Generation of C-terminally truncated amyloid-I3 peptides is dependent on y-secretase activity. Neurochem. (2002) 82(3):563–575.
  • CHURCHER I, WILLIAMS S, KERRAD S et al.: Design and synthesis of highly potent benzodiazepine y-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl) 2 (4 fluoropheny1)-4-hydroxy-N4(35)-1-methy1-2-oxo-5-phenyl-2, 3-dihydro-1H-benzo [e] [1,4] -diazepin-3-yflbutyramide by use of an asymmetric Ireland- Claisenrearrangement. Med. Chem. (2003) 46(12):2275–2278.
  • OHNO M, SAMETSKY EA, YOUNKIN LH et al: Difficiency rescues memory deficits and cholinergic dysfunction in a mouse model of alzheimer's disease. Neuron (2004) 41(1):27–33.
  • SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-I3 attenuates Alzheimer's disease-like pathology in the PDAPP mouse. Nature (1999) 400(6740):173–177.
  • ••First report of amyloid-3 immunisation asan approach to reducing Alzheimer's disease pathology.
  • NICOLL JAR, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-I3 peptide: a case report. Nat. Med. (2003) 9:448-452. 1372Expert Op/n. Investig. Drugs (2004)13(10)
  • BARD F, BARBOUR R, CANNON C et al.: Epitope and isotype specificities of antibodies to 3-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA (2003) 100(4):2023–2028.
  • MURRAY TK, WHALLEY K, ROBINSON CS et al: LY503430, a novel a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. (2003) 306(2):752–762.
  • TEAKTONG T, GRAHAM A, COURT J et al.: Alzheimer's disease is associated with a selective increase in a7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia (2003) 41(2):207–211.
  • NORDBERG A, HELLSTROM-LINDAHL E, LEE M et al.: Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). Neurochem. (2002) 81(3):655–658.
  • HELLSTROM-LINDAHL E, COURT J, KEVERNE J et al.: Nicotine reduces AP in the brain and cerebral vessels of APPsw mice. Ear. Neurosc. (2004) 19(10):2703–2710.
  • BROOKS DJ, FREY KA, MAREK KL et al.: Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neural. (2003) 184\(Suppl. 1):568–579.
  • ••Good summary of the use of neuroimagingin Parkinson's disease.
  • WHONE AL, WATTS RL, STOSSL AJ et al.: Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neural. (2003) 54(1): 93–101.
  • •A report of the effects of a dopamine agonist ropinerole on the progression of Parkinson's disease.
  • GILL SS, PATEL NK, HOTTON GR et al.: Direct brain infusion of glial cell line- derived neurotrophic factor in Parkinson's disease. Nat. Med. (2003) 9(5):589–595.
  • OKAMURA N, SUEEMOTO T, SHIMADZU H et al.: Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J. Neurosci. (2004) 24(10): 2535–2541.
  • KLUNK WE, ENGLER H, NORDBERG A et al.: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neural. (2004) 55(3):306–319.
  • DAWSON TM, DAWSON VL: Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. (2002) 5 (Suppl. S):1058–1061.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.